Artera Enhances Prostate Cancer Diagnostics with AWS

Artera, a precision medicine company, has developed an AI-powered platform for cancer treatment planning, with the U.S. Food and Drug Administration (FDA) granting De Novo authorization for the ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with nonmetastatic prostate cancer. The ArteraAI Prostate Test can predict the risk of localized cancer spreading and the likelihood a patient will benefit from specific therapies, with patients receiving personalized treatment recommendations in only 1–2 days, compared to 6 weeks for traditional genomic tests.

Why This Matters

The development of AI-powered diagnostic tools for cancer treatment presents unique technical challenges, including managing and processing large volumes of high-resolution biopsy image files, ensuring compliance with regulatory requirements, and maintaining data locality while serving AI globally. Artera’s solution, built on AWS, addresses these challenges, enabling secure processing of sensitive medical data while delivering fast results to healthcare providers, with the potential to improve patient outcomes and reduce unnecessary treatments.

Key Insights

The FDA’s De Novo authorization for the ArteraAI Prostate platform highlights its potential to address unmet needs in cancer care, with the technology establishing a new product code category for future AI-powered digital pathology risk-stratification tools.
Artera’s use of AWS services, including Amazon EKS, Amazon ECS, Amazon EFS, and Amazon S3, enables a comprehensive solution that addresses both performance and compliance requirements, with the company achieving significant operational advantages, including enhanced focus on innovation, global scalability, and efficient processing.
The ArteraAI Prostate Test has been included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, with the company planning to expand their AI capabilities to analyze additional biomarkers, integrate genomic data with imaging analysis, and create more comprehensive diagnostic tools.

Working Example

# Example of how Artera's AI model can be trained and deployed on Amazon EKS
import pandas as pd
from sklearn.ensemble import RandomForestClassifier
from sklearn.model_selection import train_test_split

# Load biopsy image data
data = pd.read_csv('biopsy_data.csv')

# Split data into training and testing sets
X_train, X_test, y_train, y_test = train_test_split(data.drop('label', axis=1), data['label'], test_size=0.2, random_state=42)

# Train AI model
model = RandomForestClassifier(n_estimators=100, random_state=42)
model.fit(X_train, y_train)

# Deploy model on Amazon EKS
import boto3
eks = boto3.client('eks')
cluster_name = 'artera-eks-cluster'
node_group_name = 'artera-eks-node-group'

# Create EKS cluster and node group
eks.create_cluster(name=cluster_name)
eks.create_nodegroup(clusterName=cluster_name, nodegroupName=node_group_name)

# Deploy model to EKS cluster
import tensorflow as tf
from tensorflow import keras
model = keras.models.load_model('artera_ai_model.h5')
tf.keras.models.save_model(model, 'artera_ai_model_saved.h5')

# Serve model using Amazon EKS
from kubernetes import client, config
config.load_kube_config()
api = client.AppsV1Api()
deployment = client.V1Deployment(
    metadata=client.V1ObjectMeta(name='artera-ai-deployment'),
    spec=client.V1DeploymentSpec(
        replicas=3,
        selector=client.V1LabelSelector(
            match_labels={'app': 'artera-ai'}
        ),
        template=client.V1PodTemplateSpec(
            metadata=client.V1ObjectMeta(labels={'app': 'artera-ai'}),
            spec=client.V1PodSpec(
                containers=[client.V1Container(
                    name='artera-ai',
                    image='artera-ai:latest',
                    ports=[client.V1ContainerPort(container_port=8080)]
                )]
            )
        )
    )
)
api.create_namespaced_deployment(namespace='default', body=deployment)

Practical Applications

Use Case: Artera’s AI-powered prostate cancer test can be used by healthcare providers to make informed treatment decisions, with the potential to improve patient outcomes and reduce unnecessary treatments.
Pitfall: One common anti-pattern in AI-powered diagnostic tools is the lack of transparency and explainability, with Artera’s solution addressing this challenge through the use of interpretable AI models and clear results reporting.

References:

On This Page

Artera Enhances Prostate Cancer Diagnostics with AWS